IOVA - Company ID 0001425205
The table below shows IOVANCE BIOTHERAPEUTICS, INC.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$72.07M | -$103.69M | -$122.28M | -$99.81M | -$73.80M | -$62.39M |
| Capital expenditure | $6.61M | $6.21M | $4.17M | $5.66M | $11.44M | $10.71M |
| Investing cash flow | $11.39M | $15.87M | -$111.51M | $153.40M | $86.52M | $77.21M |
| Dividends paid | - | - | - | - |
IOVANCE BIOTHERAPEUTICS, INC. reported operating cash flow of -$302.41M for fiscal year 2025. That is up 14.3% from -$352.98M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$32.67M (FY 2016) to -$302.41M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $94.33M | $143.31M | $193.58M | $258.17M | $1.42M | $50.36M |